Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a randomized controlled trial of isolated patients with diabetes admitted to Nordsjællands Hospital with or without COVID-19-pneumonia. A continuous glucose monitoring (CGM) based system with transmission of glucose data to a central system is used for remote monitoring of glucose levels and compared to standard finger-prick glucose. Blinded (to patients) CGM is mounted in the finger-prick group.
Description: TIR is presented in percent of time in which the participants' glucose values are in different glucose ranges.
Measure: Time In Range (TIR) for blood glucose Time: 1-2 weeksDescription: Saved patient-personnel contacts related to blood glucose measurements, incl. time healthcare providers spent on diabetes related tasks and PPE related tasks, during the patients' hospitalization.
Measure: Saved patient-personnel contacts related to blood glucose measurements. Time: 1-2 weeksDescription: Additional glucose outcomes based on data from Dexcom G6 are for example Time Above Range (TAR), Time Below Range (TBR), average glucose, variance in glucose (CV), etc.
Measure: Glucose variations during hospitalization Time: 1-2 weeksDescription: That is: Tablet-based and insulin-based regimens and number of times that sliding scale insulin (including dose of insulin) has been administered for each patient.
Measure: Blood glucose lowering interventions Time: 1-2 weeksDescription: Number of techincal errors during the sensors lifetime.
Measure: CGM sensor performance Time: 1-2 weeksDescription: Hospital death (yes/no), length of stay at hospital, need for respiratory support (yes/no) and intensive care (yes/no), recovered vs. fatal (death within 60 days from admission).
Measure: Course of hospital stay. Time: 1-2 weeks